Galactose: Difference between revisions
→Clinical significance: added additional information regarding a study on conditional flavor avoidance in female rats |
m systematic name of glucose |
||
(35 intermediate revisions by 27 users not shown) | |||
Line 1: | Line 1: | ||
⚫ | |||
{{short description|Monosaccharide sugar}} |
{{short description|Monosaccharide sugar}} |
||
⚫ | |||
{{Chembox |
{{Chembox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| Watchedfields = changed |
| Watchedfields = changed |
||
| Name = {{sm|d}}-Galactose |
| Name = {{sm|d}}-Galactose |
||
| verifiedrevid = 456367432 |
| verifiedrevid = 456367432 |
||
| ImageFile = Galactose-3D-balls.png |
| ImageFile = Galactose-3D-balls.png |
||
| ImageFileL1 = Beta-D-Galactopyranose.svg |
| ImageFileL1 = Beta-D-Galactopyranose.svg |
||
| ImageCaptionL1 = [[Haworth projection]] of<br/>β-{{sm|d}}-galactopyranose |
| ImageCaptionL1 = [[Haworth projection]] of<br />β-{{sm|d}}-galactopyranose |
||
| ImageSizeL1 = |
| ImageSizeL1 = |
||
| ImageFileR1 = DGalactose Fischer.svg |
| ImageFileR1 = DGalactose Fischer.svg |
||
| ImageCaptionR1 = [[Fischer projection]] of<br/>{{sm|d}}-galactose |
| ImageCaptionR1 = [[Fischer projection]] of<br />{{sm|d}}-galactose |
||
| ImageSizeR1 = 70 px |
| ImageSizeR1 = 70 px |
||
| IUPACName = |
| IUPACName = Galactose |
||
|SystematicName=(2''R'',3''S'',4''S'',5''R'',6)-2,3,4,5,6-Pentahydroxyhexanal |
|||
| OtherNames = |
| OtherNames = Brain sugar |
||
|Section1={{Chembox Identifiers |
| Section1 = {{Chembox Identifiers |
||
| IUPHAR_ligand = 4646 |
| IUPHAR_ligand = 4646 |
||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
Line 29: | Line 30: | ||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChIKey = WQZGKKKJIJFFOK-PHYPRBDBSA-N |
| StdInChIKey = WQZGKKKJIJFFOK-PHYPRBDBSA-N |
||
| Beilstein = 1724619 |
|||
| CASNo_Ref = {{cascite|changed|CAS}} |
| CASNo_Ref = {{cascite|changed|CAS}} |
||
| CASNo = 59-23-4 |
| CASNo = 59-23-4 |
||
| PubChem = 439357 |
| PubChem = 439357 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
| UNII_Ref = {{fdacite|correct|FDA}} |
||
| UNII = X2RN3Q8DNE |
| UNII = X2RN3Q8DNE |
||
| ChEBI_Ref = {{ebicite|correct|EBI}} |
| ChEBI_Ref = {{ebicite|correct|EBI}} |
||
| ChEBI = 28061 |
| ChEBI = 28061 |
||
Line 39: | Line 41: | ||
| MeSHName = Galactose |
| MeSHName = Galactose |
||
}} |
}} |
||
|Section2={{Chembox Properties |
| Section2 = {{Chembox Properties |
||
| C=6|H=12|O=6 |
| C=6|H=12|O=6 |
||
| Appearance = White solid<ref name=GESTIS>{{GESTIS|ZVG=100237}}</ref> |
| Appearance = White solid<ref name=GESTIS>{{GESTIS|ZVG=100237}}</ref> |
||
Line 46: | Line 48: | ||
| MeltingPtC = 168-170 |
| MeltingPtC = 168-170 |
||
| MeltingPt_ref = <ref name=GESTIS/> |
| MeltingPt_ref = <ref name=GESTIS/> |
||
| BoilingPt = |
| BoilingPt = |
||
| Solubility = 650 g/L (20 °C)<ref name=GESTIS/> |
| Solubility = 650 g/L (20 °C)<ref name=GESTIS/> |
||
| MagSus = -103.00·10<sup>−6</sup> cm<sup>3</sup>/mol |
| MagSus = -103.00·10<sup>−6</sup> cm<sup>3</sup>/mol |
||
}} |
}} |
||
|Section6={{Chembox Pharmacology |
| Section6 = {{Chembox Pharmacology |
||
| ATCCode_prefix = V04 |
| ATCCode_prefix = V04 |
||
| ATCCode_suffix = CE01 |
| ATCCode_suffix = CE01 |
||
| ATC_Supplemental = {{ATC|V08|DA02}} ([[microparticle]]s) |
| ATC_Supplemental = {{ATC|V08|DA02}} ([[microparticle]]s) |
||
}} |
}} |
||
|Section7={{Chembox Hazards |
| Section7 = {{Chembox Hazards |
||
| NFPA-H = 1 |
| NFPA-H = 1 |
||
| NFPA-F = 0 |
| NFPA-F = 0 |
||
| NFPA-R = 0 |
| NFPA-R = 0 |
||
| MainHazards = |
| MainHazards = |
||
| FlashPt = |
| FlashPt = |
||
| AutoignitionPt = |
| AutoignitionPt = |
||
}} |
}} |
||
}} |
}} |
||
'''Galactose''' ({{IPAc-en|g|ə|ˈ|l|æ|k|t|oʊ|s}}, ''[[wikt:galacto-|galacto-]]'' + ''[[wikt:-ose#Suffix 2|-ose]]'', "milk sugar") sometimes abbreviated '''Gal''', is a [[monosaccharide]] |
'''Galactose''' ({{IPAc-en|g|ə|ˈ|l|æ|k|t|oʊ|s}}, ''[[wikt:galacto-|galacto-]]'' + ''[[wikt:-ose#Suffix 2|-ose]]'', "milk sugar"), sometimes abbreviated '''Gal''', is a [[monosaccharide]] sugar that is about as [[sweetness|sweet]] as [[glucose]], and about 65% as sweet as [[sucrose]].<ref>{{cite book|url=https://books.google.com/books?id=db5QAwAAQBAJ&pg=PA264|title=Optimising Sweet Taste in Foods| vauthors = Spillane WJ |date=2006-07-17|publisher=Woodhead Publishing|isbn=9781845691646|pages=264|language=en}}</ref> It is an [[aldohexose]] and a C-4 [[epimer]] of glucose.<ref>{{Cite book |url= https://books.google.com/books?id=QOoPlLgN5UMC&pg=PA43 |title=Organic Reactions Stereochemistry And Mechanism (Through Solved Problems) | vauthors = Kalsi PS |date=2007 |publisher=New Age International |isbn=9788122417661 |pages=43 |language=en}}</ref> A galactose molecule linked with a glucose molecule forms a [[lactose]] molecule. |
||
[[Galactan]] is a [[polymer]]ic form of galactose found in [[hemicellulose]], and forming the core of the galactans, a class of natural polymeric carbohydrates.<ref>{{Cite book |url= https://books.google.com/books?id=GDuy5zL6eRAC&pg=PA78 |title= The Antibodies |last1=Zanetti |first1=Maurizio |last2=Capra |first2=Donald J. | name-list-style = vanc |date=2003-09-02 |publisher=CRC Press |isbn=9780203216514 | pages=78 }}</ref> |
[[Galactan]] is a [[polymer]]ic form of galactose found in [[hemicellulose]], and forming the core of the galactans, a class of natural polymeric carbohydrates.<ref>{{Cite book |url= https://books.google.com/books?id=GDuy5zL6eRAC&pg=PA78 |title= The Antibodies |last1=Zanetti |first1=Maurizio |last2=Capra |first2=Donald J. | name-list-style = vanc |date=2003-09-02 |publisher=CRC Press |isbn=9780203216514 | pages=78 }}</ref> |
||
D-Galactose is also known as brain sugar since it is a component of [[glycoprotein]]s (oligosaccharide-protein compounds) found in [[Nerve tissue|nerve]] tissue.<ref>{{Cite web |title=16.3 Important Hexoses {{!}} The Basics of General, Organic, and Biological Chemistry |url=https://courses.lumenlearning.com/suny-orgbiochemistry/chapter/important-hexoses/ |access-date=2022-05-06 |website=courses.lumenlearning.com}}</ref> |
|||
==Etymology== |
==Etymology== |
||
The word ''galactose'' was coined by Charles Weissman<ref>{{cite web|title=Charles Weismann in the 1940 Census | work = Ancestry|url=https://www.ancestry.com/1940-census/usa/New-York/Charles-Weismann_86gdp |access-date=26 December 2017|language=en}}</ref> in the mid |
The word ''galactose'' was coined by Charles Weissman<ref>{{cite web|title=Charles Weismann in the 1940 Census | work = Ancestry|url=https://www.ancestry.com/1940-census/usa/New-York/Charles-Weismann_86gdp |access-date=26 December 2017|language=en}}</ref> in the mid-19th century and is derived from Greek ''γαλακτος'', ''galaktos,'' (of milk) and the generic chemical suffix for sugars ''[[-ose]]''.<ref>{{cite book|last1=Bhat|first1=Paike Jayadeva | name-list-style = vanc |title=Galactose Regulon of Yeast: From Genetics to Systems Biology |url=https://books.google.com/books?id=ofEx-CsVlIAC&q=galactose+is+coined+by&pg=PA127|publisher=Springer Science & Business Media|access-date=26 December 2017|language=en|date=2 March 2008|isbn=9783540740155}}</ref> The etymology is comparable to that of the word ''[[lactose]]'' in that both contain roots meaning "milk sugar". Lactose is a [[disaccharide]] of galactose plus [[glucose]]. |
||
==Structure and isomerism== |
==Structure and isomerism== |
||
Galactose exists in both open-chain and cyclic form. The open-chain form has a [[carbonyl]] at the end of the chain. |
Galactose exists in both open-chain and cyclic form. The open-chain form has a [[carbonyl]] at the end of the chain. |
||
Four isomers are cyclic, two of them with a [[pyranose]] (six-membered) ring, two with a [[furanose]] (five-membered) ring. Galactofuranose occurs in bacteria, fungi and protozoa,<ref>{{cite journal | vauthors = Nassau PM, Martin SL, Brown RE, Weston A, Monsey D, McNeil MR, Duncan K | display-authors = 6 | title = Galactofuranose biosynthesis in Escherichia coli K-12: identification and cloning of UDP-galactopyranose mutase | journal = Journal of Bacteriology | volume = 178 | issue = 4 | pages = 1047–52 | date = February 1996 | pmid = 8576037 | pmc = 177764 | url = | doi=10.1128/jb.178.4.1047-1052.1996}}</ref><ref>{{cite journal | vauthors = Tefsen B, Ram AF, van Die I, Routier FH | title = Galactofuranose in eukaryotes: aspects of biosynthesis and functional impact | journal = Glycobiology | volume = 22 | issue = 4 | pages = 456–69 | date = April 2012 | pmid = 21940757 | doi = 10.1093/glycob/cwr144 | doi-access = free }}</ref> and is recognized by a putative chordate immune lectin [[intelectin]] through its exocyclic 1,2-diol. In the cyclic form there are two [[anomer]]s, named alpha and beta, since the transition from the open-chain form to the cyclic form involves the creation of a new [[stereocenter]] at the site of the open-chain |
Four isomers are cyclic, two of them with a [[pyranose]] (six-membered) ring, two with a [[furanose]] (five-membered) ring. Galactofuranose occurs in bacteria, fungi and protozoa,<ref>{{cite journal | vauthors = Nassau PM, Martin SL, Brown RE, Weston A, Monsey D, McNeil MR, Duncan K | display-authors = 6 | title = Galactofuranose biosynthesis in Escherichia coli K-12: identification and cloning of UDP-galactopyranose mutase | journal = Journal of Bacteriology | volume = 178 | issue = 4 | pages = 1047–52 | date = February 1996 | pmid = 8576037 | pmc = 177764 | url = | doi=10.1128/jb.178.4.1047-1052.1996}}</ref><ref>{{cite journal | vauthors = Tefsen B, Ram AF, van Die I, Routier FH | title = Galactofuranose in eukaryotes: aspects of biosynthesis and functional impact | journal = Glycobiology | volume = 22 | issue = 4 | pages = 456–69 | date = April 2012 | pmid = 21940757 | doi = 10.1093/glycob/cwr144 | doi-access = free }}</ref> and is recognized by a putative chordate immune lectin [[intelectin]] through its exocyclic 1,2-diol. In the cyclic form there are two [[anomer]]s, named alpha and beta, since the transition from the open-chain form to the cyclic form involves the creation of a new [[stereocenter]] at the site of the open-chain carbonyl.<ref name="Ophardt, C. Galactose">{{Cite web |url=http://elmhcx9.elmhurst.edu/~chm/vchembook/543galactose.html |title=Ophardt, C. Galactose |access-date=2015-11-26 |archive-url=https://web.archive.org/web/20060908164848/http://elmhcx9.elmhurst.edu/~chm/vchembook/543galactose.html |archive-date=2006-09-08 |url-status=dead }}</ref> |
||
The [[Infrared spectroscopy|IR spectra]] for galactose shows a broad, strong stretch from roughly wavenumber 2500 cm<sup>−1</sup> to wavenumber 3700 cm<sup>−1</sup>.<ref name=":1">{{Cite journal|last1=Tunki|first1=Lakshmi|last2=Kulhari|first2=Hitesh|last3=Vadithe|first3=Lakshma Nayak|last4=Kuncha|first4=Madhusudana|last5=Bhargava|first5=Suresh|last6=Pooja|first6=Deep|last7=Sistla|first7=Ramakrishna|date=2019-09-01|title=Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment|url=https://www.sciencedirect.com/science/article/pii/S0928098719302416|journal=European Journal of Pharmaceutical Sciences|language=en|volume=137|pages=104978|doi=10.1016/j.ejps.2019.104978|pmid=31254645|s2cid=195764874|issn=0928-0987}}</ref> |
|||
The [[Proton nuclear magnetic resonance|Proton NMR]] spectra for galactose includes peaks at 4.7 ppm (D<sub>2</sub>O), 4.15 ppm (−CH<sub>2</sub>OH), 3.75, 3.61, 3.48 and 3.20 ppm (−CH<sub>2</sub> of ring), 2.79–1.90 ppm (−OH).<ref name=":1" /> |
|||
[[File:D-Galactose Haworth.svg|thumb|left|upright=1.5|Cyclic forms of galactose]] |
[[File:D-Galactose Haworth.svg|thumb|left|upright=1.5|Cyclic forms of galactose]] |
||
[[File:Galactose Sessel-Konformation.png|none|thumb|390x390px|Chair conformation of D- |
[[File:Galactose Sessel-Konformation.png|none|thumb|390x390px|Chair conformation of D-galactopyranose]] |
||
{{clear}} |
|||
==Relationship to lactose== |
==Relationship to lactose== |
||
Galactose is a [[monosaccharide]]. When combined with |
Galactose is a [[monosaccharide]]. When combined with glucose (another monosaccharide) through a [[condensation reaction]], the result is a disaccharide called lactose. The [[hydrolysis]] of lactose to glucose and galactose is [[catalyzed]] by the [[enzyme]]s [[lactase]] and [[beta-galactosidase|β-galactosidase]]. The latter is produced by the [[Lac operon|''lac'' operon]] in ''[[Escherichia coli]]''.<ref>{{Citation |last=Sanganeria |first=Tanisha |title=Genetics, Inducible Operon |date=2023 |url=http://www.ncbi.nlm.nih.gov/books/NBK564361/ |work=StatPearls |access-date=2023-10-24 |place=Treasure Island (FL) |publisher=StatPearls Publishing |pmid=33232031 |last2=Bordoni |first2=Bruno}}</ref> |
||
In nature, lactose is found primarily in milk and milk products. Consequently, various food products made with dairy-derived ingredients can contain lactose.<ref>{{cite web |url=http://digestive.niddk.nih.gov/ddiseases/pubs/lactoseintolerance/ |title=Lactose Intolerance – National Digestive Diseases Information Clearinghouse |last=Staff <!-- Verified: No author provided on page. --> |work=digestive.niddk.nih.gov |date=June 2009 |access-date=January 11, 2014 |archive-url=https://web.archive.org/web/20111125192619/http://digestive.niddk.nih.gov/ddiseases/pubs/lactoseintolerance/ |archive-date=November 25, 2011 |url-status=dead }}</ref> Galactose [[metabolism]], which converts galactose into glucose, is carried out by the three principal enzymes in a mechanism known as the [[Leloir pathway]]. The enzymes are listed in the order of the metabolic pathway: galactokinase (GALK), galactose-1-phosphate uridyltransferase (GALT), and UDP-galactose-4’-epimerase (GALE).{{Citation needed|date=February 2021}} |
In nature, lactose is found primarily in milk and milk products. Consequently, various food products made with dairy-derived ingredients can contain lactose.<ref>{{cite web |url=http://digestive.niddk.nih.gov/ddiseases/pubs/lactoseintolerance/ |title=Lactose Intolerance – National Digestive Diseases Information Clearinghouse |last=Staff <!-- Verified: No author provided on page. --> |work=digestive.niddk.nih.gov |date=June 2009 |access-date=January 11, 2014 |archive-url=https://web.archive.org/web/20111125192619/http://digestive.niddk.nih.gov/ddiseases/pubs/lactoseintolerance/ |archive-date=November 25, 2011 |url-status=dead }}</ref> Galactose [[metabolism]], which converts galactose into glucose, is carried out by the three principal enzymes in a mechanism known as the [[Leloir pathway]]. The enzymes are listed in the order of the metabolic pathway: galactokinase (GALK), galactose-1-phosphate uridyltransferase (GALT), and UDP-galactose-4’-epimerase (GALE).{{Citation needed|date=February 2021}} |
||
In human [[lactation]], |
In human [[lactation]], galactose is required in a 1 to 1 ratio with glucose to enable the [[mammary glands]] to synthesize and secrete lactose. In a study where women were fed a diet containing galactose, 69 ± 6% of glucose and 54 ± 4% of galactose in the lactose they produced were derived directly from plasma glucose, while 7 ± 2% of the glucose and 12 ± 2% of the galactose in the lactose, were derived directly from plasma galactose. 25 ± 8% of the glucose and 35 ± 6% of the galactose was synthesized from smaller molecules such as glycerol or acetate in a process referred to in the paper as hexoneogenesis. This suggests that the synthesis of galactose is supplemented by direct uptake and of use of plasma galactose when present.<ref name=sunehag>{{cite journal | vauthors = Sunehag A, Tigas S, Haymond MW | title = Contribution of plasma galactose and glucose to milk lactose synthesis during galactose ingestion | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 88 | issue = 1 | pages = 225–9 | date = January 2003 | pmid = 12519857 | doi = 10.1210/jc.2002-020768 | doi-access = free }}</ref> |
||
==Metabolism== |
==Metabolism== |
||
Line 95: | Line 102: | ||
|} |
|} |
||
[[File:Leloir pathway.png|300px|thumb|right|Galactose metabolism]] |
[[File:Leloir pathway.png|300px|thumb|right|Galactose metabolism]] |
||
Glucose is more stable than galactose and is less susceptible to the formation of nonspecific glycoconjugates, molecules with at least one sugar attached to a protein or lipid. Many speculate that it is for this reason that a pathway for rapid conversion from galactose to glucose has been [[ |
Glucose is more stable than galactose and is less susceptible to the formation of nonspecific glycoconjugates, molecules with at least one sugar attached to a protein or lipid. Many speculate that it is for this reason that a pathway for rapid conversion from galactose to glucose has been [[Conserved sequence|highly conserved]] among many species.<ref name=OMMBID72>{{cite book |chapter-url=https://ommbid.mhmedical.com/content.aspx?bookid=971§ionid=62672411 |chapter-url-access=subscription |title=The Online Metabolic and Molecular Bases of Inherited Disease |chapter=Galactosemia |vauthors=Fridovich-Keil JL, Walter JH |veditors=Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson KM, Mitchell G |access-date=2018-06-25 |archive-date=2018-06-26 |archive-url=https://web.archive.org/web/20180626030220/https://ommbid.mhmedical.com/content.aspx?bookid=971§ionid=62672411 |url-status=dead }}<br />a 4 b 21 c 22 d 22</ref> |
||
The main pathway of galactose metabolism is the [[Leloir pathway]]; humans and other species, however, have been noted to contain several alternate pathways, such as the [[De Ley Doudoroff Pathway]]. The Leloir pathway consists of the latter stage of a two-part process that converts β-D-galactose to [[Uridine diphosphate glucose|UDP-glucose]]. The initial stage is the conversion of β-D-galactose to α-D-galactose by the enzyme, mutarotase (GALM). The Leloir pathway then carries out the conversion of α-D-galactose to UDP-glucose via three principal enzymes: Galactokinase (GALK) phosphorylates α-D-galactose to galactose-1-phosphate, or Gal-1-P; Galactose-1-phosphate uridyltransferase (GALT) transfers a UMP group from UDP-glucose to Gal-1-P to form UDP-galactose; and finally, UDP galactose-4’-epimerase (GALE) interconverts UDP-galactose and UDP-glucose, thereby completing the pathway.<ref name=Bosch07>{{cite journal | vauthors = Bosch AM | title = Classical galactosaemia revisited | journal = Journal of Inherited Metabolic Disease | volume = 29 | issue = 4 | pages = 516–25 | date = August 2006 | pmid = 16838075 | doi = 10.1007/s10545-006-0382-0 | s2cid = 16382462 }}<br /> a 517 b 516 c 519</ref> |
The main pathway of galactose metabolism is the [[Leloir pathway]]; humans and other species, however, have been noted to contain several alternate pathways, such as the [[De Ley Doudoroff Pathway]]. The Leloir pathway consists of the latter stage of a two-part process that converts β-D-galactose to [[Uridine diphosphate glucose|UDP-glucose]]. The initial stage is the conversion of β-D-galactose to α-D-galactose by the enzyme, mutarotase (GALM). The Leloir pathway then carries out the conversion of α-D-galactose to UDP-glucose via three principal enzymes: Galactokinase (GALK) phosphorylates α-D-galactose to galactose-1-phosphate, or Gal-1-P; Galactose-1-phosphate uridyltransferase (GALT) transfers a UMP group from UDP-glucose to Gal-1-P to form UDP-galactose; and finally, UDP galactose-4’-epimerase (GALE) interconverts UDP-galactose and UDP-glucose, thereby completing the pathway.<ref name=Bosch07>{{cite journal | vauthors = Bosch AM | title = Classical galactosaemia revisited | journal = Journal of Inherited Metabolic Disease | volume = 29 | issue = 4 | pages = 516–25 | date = August 2006 | pmid = 16838075 | doi = 10.1007/s10545-006-0382-0 | s2cid = 16382462 }}<br /> a 517 b 516 c 519</ref> |
||
The above mechanisms for galactose metabolism are necessary because the human body cannot directly convert galactose into energy, and must first go through one of these processes in order to utilize the sugar.<ref>{{Cite book|last1=Berg|first1=Jeremy M.|last2=Tymoczko|first2=John L.|last3=Stryer|first3=Lubert|date=2013|title=Stryer Biochemie|url=http://dx.doi.org/10.1007/978-3-8274-2989-6|doi=10.1007/978-3-8274-2989-6|isbn=978-3-8274-2988-9}}</ref> |
|||
[[Galactosemia]] is an inability to properly break down galactose due to a genetically inherited mutation in one of the enzymes in the Leloir pathway. As a result, the consumption of even small quantities is harmful to galactosemics.<ref>{{cite journal|url=https://www.ncbi.nlm.nih.gov/books/NBK1518|title=Classic Galactosemia and Clinical Variant Galactosemia| first = Gerard T | last = Berry | name-list-style = vanc |journal=Nih.gov|access-date=17 May 2015|publisher=University of Washington, Seattle|year=1993|pmid=20301691}}</ref> |
[[Galactosemia]] is an inability to properly break down galactose due to a genetically inherited mutation in one of the enzymes in the Leloir pathway. As a result, the consumption of even small quantities is harmful to galactosemics.<ref>{{cite journal|url=https://www.ncbi.nlm.nih.gov/books/NBK1518|title=Classic Galactosemia and Clinical Variant Galactosemia| first = Gerard T | last = Berry | name-list-style = vanc |journal=Nih.gov|access-date=17 May 2015|publisher=University of Washington, Seattle|year=1993|pmid=20301691}}</ref> |
||
Line 105: | Line 114: | ||
==Clinical significance== |
==Clinical significance== |
||
Chronic systemic exposure of [[mice]], [[rat]]s, and ''[[Drosophila]]'' to D-galactose causes the acceleration of [[senescence]] (aging). It has been reported that high dose exposure of D-galactose (120 mg/ |
Chronic systemic exposure of [[mice]], [[rat]]s, and ''[[Drosophila]]'' to D-galactose causes the acceleration of [[senescence]] (aging). It has been reported that high dose exposure of D-galactose (120 mg/kg) can cause reduced sperm concentration and sperm motility in rodents and has been extensively used as an aging model when administered subcutaneously.<ref>{{cite journal | vauthors = Pourmemar E, Majdi A, Haramshahi M, Talebi M, Karimi P, Sadigh-Eteghad S | title = Intranasal Cerebrolysin Attenuates Learning and Memory Impairments in D-galactose-Induced Senescence in Mice | journal = Experimental Gerontology | volume = 87 | issue = Pt A | pages = 16–22 | date = January 2017 | pmid = 27894939 | doi = 10.1016/j.exger.2016.11.011 | s2cid = 40793896 }}</ref><ref>{{cite journal | vauthors = Cui X, Zuo P, Zhang Q, Li X, Hu Y, Long J, Packer L, Liu J | title = Chronic systemic D-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: protective effects of R-alpha-lipoic acid | journal = Journal of Neuroscience Research | volume = 84 | issue = 3 | pages = 647–54 | date = August 2006 | pmid = 16710848 | doi = 10.1002/jnr.20899 | s2cid = 13641006 }}</ref><ref>{{cite journal | vauthors = Zhou YY, Ji XF, Fu JP, Zhu XJ, Li RH, Mu CK, Wang CL, Song WW | display-authors = 6 | title = Gene Transcriptional and Metabolic Profile Changes in Mimetic Aging Mice Induced by D-Galactose | journal = PLOS ONE | volume = 10 | issue = 7 | pages = e0132088 | date = 2015-07-15 | pmid = 26176541 | pmc = 4503422 | doi = 10.1371/journal.pone.0132088 | bibcode = 2015PLoSO..1032088Z | doi-access = free }}</ref> |
||
Two studies have suggested a possible link between galactose in milk and [[ovarian cancer]].<ref>{{cite journal | vauthors = Cramer DW | title = Lactase persistence and milk consumption as determinants of ovarian cancer risk | journal = American Journal of Epidemiology | volume = 130 | issue = 5 | pages = 904–10 | date = November 1989 | pmid = 2510499 | doi=10.1093/oxfordjournals.aje.a115423}}</ref><ref>{{cite journal | vauthors = Cramer DW, Harlow BL, Willett WC, Welch WR, Bell DA, Scully RE, Ng WG, Knapp RC | title = Galactose consumption and metabolism in relation to the risk of ovarian cancer | journal = Lancet | volume = 2 | issue = 8654 | pages = 66–71 | date = July 1989 | pmid = 2567871 | doi = 10.1016/S0140-6736(89)90313-9 | s2cid = 34304536 }}</ref> Other studies show no correlation, even in the presence of defective galactose metabolism.<ref>{{cite journal | vauthors = Goodman MT, Wu AH, Tung KH, McDuffie K, Cramer DW, Wilkens LR, Terada K, Reichardt JK, Ng WG | display-authors = 6 | title = Association of galactose-1-phosphate uridyltransferase activity and N314D genotype with the risk of ovarian cancer | journal = American Journal of Epidemiology | volume = 156 | issue = 8 | pages = 693–701 | date = October 2002 | pmid = 12370157 | doi = 10.1093/aje/kwf104 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Fung WL, Risch H, McLaughlin J, Rosen B, Cole D, Vesprini D, Narod SA | title = The N314D polymorphism of galactose-1-phosphate uridyl transferase does not modify the risk of ovarian cancer | journal = Cancer Epidemiology, Biomarkers & Prevention | volume = 12 | issue = 7 | pages = 678–80 | date = July 2003 | pmid = 12869412 }}</ref> More recently, pooled analysis done by the [[Harvard School of Public Health]] showed no specific correlation between lactose-containing foods and ovarian cancer, and showed statistically insignificant increases in risk for consumption of lactose at 30 g/day.<ref>{{cite journal | vauthors = Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Arslan A, Beeson WL, Buring JE, Fraser GE, Freudenheim JL, Goldbohm RA, Hankinson SE, Jacobs DR, Koushik A, Lacey JV, Larsson SC, Leitzmann M, McCullough ML, Miller AB, Rodriguez C, Rohan TE, Schouten LJ, Shore R, Smit E, Wolk A, Zhang SM, Smith-Warner SA | display-authors = 6 | title = Dairy products and ovarian cancer: a pooled analysis of 12 cohort studies | journal = Cancer Epidemiology, Biomarkers & Prevention | volume = 15 | issue = 2 | pages = 364–72 | date = February 2006 | pmid = 16492930 | doi = 10.1158/1055-9965.EPI-05-0484 | doi-access = |
Two studies have suggested a possible link between galactose in milk and [[ovarian cancer]].<ref>{{cite journal | vauthors = Cramer DW | title = Lactase persistence and milk consumption as determinants of ovarian cancer risk | journal = American Journal of Epidemiology | volume = 130 | issue = 5 | pages = 904–10 | date = November 1989 | pmid = 2510499 | doi=10.1093/oxfordjournals.aje.a115423}}</ref><ref>{{cite journal | vauthors = Cramer DW, Harlow BL, Willett WC, Welch WR, Bell DA, Scully RE, Ng WG, Knapp RC | title = Galactose consumption and metabolism in relation to the risk of ovarian cancer | journal = Lancet | volume = 2 | issue = 8654 | pages = 66–71 | date = July 1989 | pmid = 2567871 | doi = 10.1016/S0140-6736(89)90313-9 | s2cid = 34304536 }}</ref> Other studies show no correlation, even in the presence of defective galactose metabolism.<ref>{{cite journal | vauthors = Goodman MT, Wu AH, Tung KH, McDuffie K, Cramer DW, Wilkens LR, Terada K, Reichardt JK, Ng WG | display-authors = 6 | title = Association of galactose-1-phosphate uridyltransferase activity and N314D genotype with the risk of ovarian cancer | journal = American Journal of Epidemiology | volume = 156 | issue = 8 | pages = 693–701 | date = October 2002 | pmid = 12370157 | doi = 10.1093/aje/kwf104 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Fung WL, Risch H, McLaughlin J, Rosen B, Cole D, Vesprini D, Narod SA | title = The N314D polymorphism of galactose-1-phosphate uridyl transferase does not modify the risk of ovarian cancer | journal = Cancer Epidemiology, Biomarkers & Prevention | volume = 12 | issue = 7 | pages = 678–80 | date = July 2003 | pmid = 12869412 }}</ref> More recently, pooled analysis done by the [[Harvard School of Public Health]] showed no specific correlation between lactose-containing foods and ovarian cancer, and showed statistically insignificant increases in risk for consumption of lactose at 30 g/day.<ref>{{cite journal | vauthors = Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Arslan A, Beeson WL, Buring JE, Fraser GE, Freudenheim JL, Goldbohm RA, Hankinson SE, Jacobs DR, Koushik A, Lacey JV, Larsson SC, Leitzmann M, McCullough ML, Miller AB, Rodriguez C, Rohan TE, Schouten LJ, Shore R, Smit E, Wolk A, Zhang SM, Smith-Warner SA | display-authors = 6 | title = Dairy products and ovarian cancer: a pooled analysis of 12 cohort studies | journal = Cancer Epidemiology, Biomarkers & Prevention | volume = 15 | issue = 2 | pages = 364–72 | date = February 2006 | pmid = 16492930 | doi = 10.1158/1055-9965.EPI-05-0484 | doi-access = }}</ref> More research is necessary to ascertain possible risks.{{Citation needed|date=February 2021}} |
||
Some ongoing studies suggest galactose may have a role in treatment of [[focal segmental glomerulosclerosis]] (a kidney disease resulting in kidney failure and proteinuria).<ref name="pmid19509024">{{cite journal | vauthors = De Smet E, Rioux JP, Ammann H, Déziel C, Quérin S | title = FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy | journal = Nephrology, Dialysis, Transplantation | volume = 24 | issue = 9 | pages = 2938–40 | date = September 2009 | pmid = 19509024 | doi = 10.1093/ndt/gfp278 | doi-access = free }}</ref> This effect is likely to be a result of binding of galactose to FSGS factor.<ref>{{cite journal | vauthors = McCarthy ET, Sharma M, Savin VJ | title = Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis | journal = Clinical Journal of the American Society of Nephrology | volume = 5 | issue = 11 | pages = 2115–21 | date = November 2010 | pmid = 20966123 | doi = 10.2215/CJN.03800609 | doi-access = free }}</ref> |
Some ongoing studies suggest galactose may have a role in treatment of [[focal segmental glomerulosclerosis]] (a kidney disease resulting in kidney failure and proteinuria).<ref name="pmid19509024">{{cite journal | vauthors = De Smet E, Rioux JP, Ammann H, Déziel C, Quérin S | title = FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy | journal = Nephrology, Dialysis, Transplantation | volume = 24 | issue = 9 | pages = 2938–40 | date = September 2009 | pmid = 19509024 | doi = 10.1093/ndt/gfp278 | doi-access = free }}</ref> This effect is likely to be a result of binding of galactose to FSGS factor.<ref>{{cite journal | vauthors = McCarthy ET, Sharma M, Savin VJ | title = Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis | journal = Clinical Journal of the American Society of Nephrology | volume = 5 | issue = 11 | pages = 2115–21 | date = November 2010 | pmid = 20966123 | doi = 10.2215/CJN.03800609 | doi-access = free }}</ref> |
||
Galactose is a component of the |
Galactose is a component of the [[antigen]]s (chemical markers) present on blood cells that distinguish blood type within the [[ABO blood group system]]. In O and A antigens, there are two [[monomer]]s of galactose on the antigens, whereas in the B antigens there are three monomers of galactose.<ref name="Raven and Johnson">{{cite book|title=Understanding Biology|edition=3rd| first1 = Peter H. | last1 = Raven | first2 = George B. | last2 = Johnson |pages=203 |isbn=978-0-697-22213-8 |year=1995 | veditors = Mills CJ |publisher = WM C. Brown}}</ref> |
||
A disaccharide composed of two units of galactose, [[galactose-alpha-1,3-galactose]] (alpha-gal), has been recognized as a potential [[allergen]] present in [[mammal meat]]. [[Alpha-gal allergy]] may be triggered by [[lone star tick]] bites.{{ |
A disaccharide composed of two units of galactose, [[galactose-alpha-1,3-galactose]] (alpha-gal), has been recognized as a potential [[allergen]] present in [[mammal meat]]. [[Alpha-gal allergy]] may be triggered by [[lone star tick]] bites.<ref>{{Cite web|title=Alpha-gal syndrome - Symptoms and causes|url=https://www.mayoclinic.org/diseases-conditions/alpha-gal-syndrome/symptoms-causes/syc-20428608|access-date=2022-02-25|website=Mayo Clinic|language=en}}</ref> |
||
Galactose in sodium saccharin solution has also been found to cause conditioned flavor avoidance in adult female rats within a laboratory setting when combined with intragastric injections<ref name=":0">{{Cite journal| |
Galactose in sodium saccharin solution has also been found to cause conditioned flavor avoidance in adult female rats within a laboratory setting when combined with intragastric injections.<ref name=":0">{{Cite journal|last1=Sclafani|first1=Anthony|last2=Fanizza|first2=Lawrence J|last3=Azzara|first3=Anthony V|date=1999-08-15|title=Conditioned Flavor Avoidance, Preference, and Indifference Produced by Intragastric Infusions of Galactose, Glucose, and Fructose in Rats|url=https://www.sciencedirect.com/science/article/pii/S0031938499000530|journal=Physiology & Behavior|language=en|volume=67|issue=2|pages=227–234|doi=10.1016/S0031-9384(99)00053-0|pmid=10477054|s2cid=37225025|issn=0031-9384}}</ref> The reason for this flavor avoidance is still unknown, however it is possible that a decrease in the levels of the enzymes required to convert galactose to glucose in the liver of the rats could be responsible.<ref name=":0" /> |
||
== History == |
== History == |
||
Line 123: | Line 132: | ||
== See also == |
== See also == |
||
⚫ | |||
* [[L-galactose]] |
|||
* [[Galactogen]] |
* [[Galactogen]] |
||
⚫ | |||
== References == |
== References == |
||
Line 131: | Line 139: | ||
== External links == |
== External links == |
||
*{{Commons category-inline}} |
* {{Commons category-inline}} |
||
{{Sugar}} |
{{Sugar}} |
||
Line 138: | Line 146: | ||
[[Category:Galactose| ]] |
[[Category:Galactose| ]] |
||
[[Category:Nutrition]] |
[[Category:Nutrition]] |
||
⚫ | |||
[[Category:Pyranoses]] |
[[Category:Pyranoses]] |
||
⚫ |
Latest revision as of 08:55, 3 September 2024
| |||
Names | |||
---|---|---|---|
IUPAC name
Galactose
| |||
Systematic IUPAC name
(2R,3S,4S,5R,6)-2,3,4,5,6-Pentahydroxyhexanal | |||
Other names
Brain sugar
| |||
Identifiers | |||
3D model (JSmol)
|
|||
1724619 | |||
ChEBI | |||
ChEMBL | |||
ChemSpider | |||
KEGG | |||
MeSH | Galactose | ||
PubChem CID
|
|||
UNII | |||
| |||
| |||
Properties | |||
C6H12O6 | |||
Molar mass | 180.156 g·mol−1 | ||
Appearance | White solid[1] | ||
Odor | Odorless[1] | ||
Density | 1.5 g/cm3[1] | ||
Melting point | 168–170 °C (334–338 °F; 441–443 K)[1] | ||
650 g/L (20 °C)[1] | |||
-103.00·10−6 cm3/mol | |||
Pharmacology | |||
V04CE01 (WHO) V08DA02 (WHO) (microparticles) | |||
Hazards | |||
NFPA 704 (fire diamond) | |||
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Galactose (/ɡəˈlæktoʊs/, galacto- + -ose, "milk sugar"), sometimes abbreviated Gal, is a monosaccharide sugar that is about as sweet as glucose, and about 65% as sweet as sucrose.[2] It is an aldohexose and a C-4 epimer of glucose.[3] A galactose molecule linked with a glucose molecule forms a lactose molecule.
Galactan is a polymeric form of galactose found in hemicellulose, and forming the core of the galactans, a class of natural polymeric carbohydrates.[4]
D-Galactose is also known as brain sugar since it is a component of glycoproteins (oligosaccharide-protein compounds) found in nerve tissue.[5]
Etymology
[edit]The word galactose was coined by Charles Weissman[6] in the mid-19th century and is derived from Greek γαλακτος, galaktos, (of milk) and the generic chemical suffix for sugars -ose.[7] The etymology is comparable to that of the word lactose in that both contain roots meaning "milk sugar". Lactose is a disaccharide of galactose plus glucose.
Structure and isomerism
[edit]Galactose exists in both open-chain and cyclic form. The open-chain form has a carbonyl at the end of the chain.
Four isomers are cyclic, two of them with a pyranose (six-membered) ring, two with a furanose (five-membered) ring. Galactofuranose occurs in bacteria, fungi and protozoa,[8][9] and is recognized by a putative chordate immune lectin intelectin through its exocyclic 1,2-diol. In the cyclic form there are two anomers, named alpha and beta, since the transition from the open-chain form to the cyclic form involves the creation of a new stereocenter at the site of the open-chain carbonyl.[10]
The IR spectra for galactose shows a broad, strong stretch from roughly wavenumber 2500 cm−1 to wavenumber 3700 cm−1.[11]
The Proton NMR spectra for galactose includes peaks at 4.7 ppm (D2O), 4.15 ppm (−CH2OH), 3.75, 3.61, 3.48 and 3.20 ppm (−CH2 of ring), 2.79–1.90 ppm (−OH).[11]
Relationship to lactose
[edit]Galactose is a monosaccharide. When combined with glucose (another monosaccharide) through a condensation reaction, the result is a disaccharide called lactose. The hydrolysis of lactose to glucose and galactose is catalyzed by the enzymes lactase and β-galactosidase. The latter is produced by the lac operon in Escherichia coli.[12]
In nature, lactose is found primarily in milk and milk products. Consequently, various food products made with dairy-derived ingredients can contain lactose.[13] Galactose metabolism, which converts galactose into glucose, is carried out by the three principal enzymes in a mechanism known as the Leloir pathway. The enzymes are listed in the order of the metabolic pathway: galactokinase (GALK), galactose-1-phosphate uridyltransferase (GALT), and UDP-galactose-4’-epimerase (GALE).[citation needed]
In human lactation, galactose is required in a 1 to 1 ratio with glucose to enable the mammary glands to synthesize and secrete lactose. In a study where women were fed a diet containing galactose, 69 ± 6% of glucose and 54 ± 4% of galactose in the lactose they produced were derived directly from plasma glucose, while 7 ± 2% of the glucose and 12 ± 2% of the galactose in the lactose, were derived directly from plasma galactose. 25 ± 8% of the glucose and 35 ± 6% of the galactose was synthesized from smaller molecules such as glycerol or acetate in a process referred to in the paper as hexoneogenesis. This suggests that the synthesis of galactose is supplemented by direct uptake and of use of plasma galactose when present.[14]
Metabolism
[edit]Metabolism of common monosaccharides and some biochemical reactions of glucose |
---|
Glucose is more stable than galactose and is less susceptible to the formation of nonspecific glycoconjugates, molecules with at least one sugar attached to a protein or lipid. Many speculate that it is for this reason that a pathway for rapid conversion from galactose to glucose has been highly conserved among many species.[15]
The main pathway of galactose metabolism is the Leloir pathway; humans and other species, however, have been noted to contain several alternate pathways, such as the De Ley Doudoroff Pathway. The Leloir pathway consists of the latter stage of a two-part process that converts β-D-galactose to UDP-glucose. The initial stage is the conversion of β-D-galactose to α-D-galactose by the enzyme, mutarotase (GALM). The Leloir pathway then carries out the conversion of α-D-galactose to UDP-glucose via three principal enzymes: Galactokinase (GALK) phosphorylates α-D-galactose to galactose-1-phosphate, or Gal-1-P; Galactose-1-phosphate uridyltransferase (GALT) transfers a UMP group from UDP-glucose to Gal-1-P to form UDP-galactose; and finally, UDP galactose-4’-epimerase (GALE) interconverts UDP-galactose and UDP-glucose, thereby completing the pathway.[16]
The above mechanisms for galactose metabolism are necessary because the human body cannot directly convert galactose into energy, and must first go through one of these processes in order to utilize the sugar.[17]
Galactosemia is an inability to properly break down galactose due to a genetically inherited mutation in one of the enzymes in the Leloir pathway. As a result, the consumption of even small quantities is harmful to galactosemics.[18]
Sources
[edit]Galactose is found in dairy products, avocados, sugar beets, other gums and mucilages. It is also synthesized by the body, where it forms part of glycolipids and glycoproteins in several tissues; and is a by-product from the third-generation ethanol production process (from macroalgae).[citation needed]
Clinical significance
[edit]Chronic systemic exposure of mice, rats, and Drosophila to D-galactose causes the acceleration of senescence (aging). It has been reported that high dose exposure of D-galactose (120 mg/kg) can cause reduced sperm concentration and sperm motility in rodents and has been extensively used as an aging model when administered subcutaneously.[19][20][21] Two studies have suggested a possible link between galactose in milk and ovarian cancer.[22][23] Other studies show no correlation, even in the presence of defective galactose metabolism.[24][25] More recently, pooled analysis done by the Harvard School of Public Health showed no specific correlation between lactose-containing foods and ovarian cancer, and showed statistically insignificant increases in risk for consumption of lactose at 30 g/day.[26] More research is necessary to ascertain possible risks.[citation needed]
Some ongoing studies suggest galactose may have a role in treatment of focal segmental glomerulosclerosis (a kidney disease resulting in kidney failure and proteinuria).[27] This effect is likely to be a result of binding of galactose to FSGS factor.[28]
Galactose is a component of the antigens (chemical markers) present on blood cells that distinguish blood type within the ABO blood group system. In O and A antigens, there are two monomers of galactose on the antigens, whereas in the B antigens there are three monomers of galactose.[29]
A disaccharide composed of two units of galactose, galactose-alpha-1,3-galactose (alpha-gal), has been recognized as a potential allergen present in mammal meat. Alpha-gal allergy may be triggered by lone star tick bites.[30]
Galactose in sodium saccharin solution has also been found to cause conditioned flavor avoidance in adult female rats within a laboratory setting when combined with intragastric injections.[31] The reason for this flavor avoidance is still unknown, however it is possible that a decrease in the levels of the enzymes required to convert galactose to glucose in the liver of the rats could be responsible.[31]
History
[edit]In 1855, E. O. Erdmann noted that hydrolysis of lactose produced a substance besides glucose.[32][33]
Galactose was first isolated and studied by Louis Pasteur in 1856 and he called it "lactose".[34] In 1860, Berthelot renamed it "galactose" or "glucose lactique".[35][36] In 1894, Emil Fischer and Robert Morrell determined the configuration of galactose.[37]
See also
[edit]References
[edit]- ^ a b c d e Record in the GESTIS Substance Database of the Institute for Occupational Safety and Health
- ^ Spillane WJ (2006-07-17). Optimising Sweet Taste in Foods. Woodhead Publishing. p. 264. ISBN 9781845691646.
- ^ Kalsi PS (2007). Organic Reactions Stereochemistry And Mechanism (Through Solved Problems). New Age International. p. 43. ISBN 9788122417661.
- ^ Zanetti M, Capra DJ (2003-09-02). The Antibodies. CRC Press. p. 78. ISBN 9780203216514.
- ^ "16.3 Important Hexoses | The Basics of General, Organic, and Biological Chemistry". courses.lumenlearning.com. Retrieved 2022-05-06.
- ^ "Charles Weismann in the 1940 Census". Ancestry. Retrieved 26 December 2017.
- ^ Bhat PJ (2 March 2008). Galactose Regulon of Yeast: From Genetics to Systems Biology. Springer Science & Business Media. ISBN 9783540740155. Retrieved 26 December 2017.
- ^ Nassau PM, Martin SL, Brown RE, Weston A, Monsey D, McNeil MR, et al. (February 1996). "Galactofuranose biosynthesis in Escherichia coli K-12: identification and cloning of UDP-galactopyranose mutase". Journal of Bacteriology. 178 (4): 1047–52. doi:10.1128/jb.178.4.1047-1052.1996. PMC 177764. PMID 8576037.
- ^ Tefsen B, Ram AF, van Die I, Routier FH (April 2012). "Galactofuranose in eukaryotes: aspects of biosynthesis and functional impact". Glycobiology. 22 (4): 456–69. doi:10.1093/glycob/cwr144. PMID 21940757.
- ^ "Ophardt, C. Galactose". Archived from the original on 2006-09-08. Retrieved 2015-11-26.
- ^ a b Tunki, Lakshmi; Kulhari, Hitesh; Vadithe, Lakshma Nayak; Kuncha, Madhusudana; Bhargava, Suresh; Pooja, Deep; Sistla, Ramakrishna (2019-09-01). "Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment". European Journal of Pharmaceutical Sciences. 137: 104978. doi:10.1016/j.ejps.2019.104978. ISSN 0928-0987. PMID 31254645. S2CID 195764874.
- ^ Sanganeria, Tanisha; Bordoni, Bruno (2023), "Genetics, Inducible Operon", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 33232031, retrieved 2023-10-24
- ^ Staff (June 2009). "Lactose Intolerance – National Digestive Diseases Information Clearinghouse". digestive.niddk.nih.gov. Archived from the original on November 25, 2011. Retrieved January 11, 2014.
- ^ Sunehag A, Tigas S, Haymond MW (January 2003). "Contribution of plasma galactose and glucose to milk lactose synthesis during galactose ingestion". The Journal of Clinical Endocrinology and Metabolism. 88 (1): 225–9. doi:10.1210/jc.2002-020768. PMID 12519857.
- ^ Fridovich-Keil JL, Walter JH. "Galactosemia". In Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson KM, Mitchell G (eds.). The Online Metabolic and Molecular Bases of Inherited Disease. Archived from the original on 2018-06-26. Retrieved 2018-06-25.
a 4 b 21 c 22 d 22 - ^ Bosch AM (August 2006). "Classical galactosaemia revisited". Journal of Inherited Metabolic Disease. 29 (4): 516–25. doi:10.1007/s10545-006-0382-0. PMID 16838075. S2CID 16382462.
a 517 b 516 c 519 - ^ Berg, Jeremy M.; Tymoczko, John L.; Stryer, Lubert (2013). Stryer Biochemie. doi:10.1007/978-3-8274-2989-6. ISBN 978-3-8274-2988-9.
- ^ Berry GT (1993). "Classic Galactosemia and Clinical Variant Galactosemia". Nih.gov. University of Washington, Seattle. PMID 20301691. Retrieved 17 May 2015.
- ^ Pourmemar E, Majdi A, Haramshahi M, Talebi M, Karimi P, Sadigh-Eteghad S (January 2017). "Intranasal Cerebrolysin Attenuates Learning and Memory Impairments in D-galactose-Induced Senescence in Mice". Experimental Gerontology. 87 (Pt A): 16–22. doi:10.1016/j.exger.2016.11.011. PMID 27894939. S2CID 40793896.
- ^ Cui X, Zuo P, Zhang Q, Li X, Hu Y, Long J, Packer L, Liu J (August 2006). "Chronic systemic D-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: protective effects of R-alpha-lipoic acid". Journal of Neuroscience Research. 84 (3): 647–54. doi:10.1002/jnr.20899. PMID 16710848. S2CID 13641006.
- ^ Zhou YY, Ji XF, Fu JP, Zhu XJ, Li RH, Mu CK, et al. (2015-07-15). "Gene Transcriptional and Metabolic Profile Changes in Mimetic Aging Mice Induced by D-Galactose". PLOS ONE. 10 (7): e0132088. Bibcode:2015PLoSO..1032088Z. doi:10.1371/journal.pone.0132088. PMC 4503422. PMID 26176541.
- ^ Cramer DW (November 1989). "Lactase persistence and milk consumption as determinants of ovarian cancer risk". American Journal of Epidemiology. 130 (5): 904–10. doi:10.1093/oxfordjournals.aje.a115423. PMID 2510499.
- ^ Cramer DW, Harlow BL, Willett WC, Welch WR, Bell DA, Scully RE, Ng WG, Knapp RC (July 1989). "Galactose consumption and metabolism in relation to the risk of ovarian cancer". Lancet. 2 (8654): 66–71. doi:10.1016/S0140-6736(89)90313-9. PMID 2567871. S2CID 34304536.
- ^ Goodman MT, Wu AH, Tung KH, McDuffie K, Cramer DW, Wilkens LR, et al. (October 2002). "Association of galactose-1-phosphate uridyltransferase activity and N314D genotype with the risk of ovarian cancer". American Journal of Epidemiology. 156 (8): 693–701. doi:10.1093/aje/kwf104. PMID 12370157.
- ^ Fung WL, Risch H, McLaughlin J, Rosen B, Cole D, Vesprini D, Narod SA (July 2003). "The N314D polymorphism of galactose-1-phosphate uridyl transferase does not modify the risk of ovarian cancer". Cancer Epidemiology, Biomarkers & Prevention. 12 (7): 678–80. PMID 12869412.
- ^ Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Arslan A, Beeson WL, et al. (February 2006). "Dairy products and ovarian cancer: a pooled analysis of 12 cohort studies". Cancer Epidemiology, Biomarkers & Prevention. 15 (2): 364–72. doi:10.1158/1055-9965.EPI-05-0484. PMID 16492930.
- ^ De Smet E, Rioux JP, Ammann H, Déziel C, Quérin S (September 2009). "FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy". Nephrology, Dialysis, Transplantation. 24 (9): 2938–40. doi:10.1093/ndt/gfp278. PMID 19509024.
- ^ McCarthy ET, Sharma M, Savin VJ (November 2010). "Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis". Clinical Journal of the American Society of Nephrology. 5 (11): 2115–21. doi:10.2215/CJN.03800609. PMID 20966123.
- ^ Raven PH, Johnson GB (1995). Mills CJ (ed.). Understanding Biology (3rd ed.). WM C. Brown. p. 203. ISBN 978-0-697-22213-8.
- ^ "Alpha-gal syndrome - Symptoms and causes". Mayo Clinic. Retrieved 2022-02-25.
- ^ a b Sclafani, Anthony; Fanizza, Lawrence J; Azzara, Anthony V (1999-08-15). "Conditioned Flavor Avoidance, Preference, and Indifference Produced by Intragastric Infusions of Galactose, Glucose, and Fructose in Rats". Physiology & Behavior. 67 (2): 227–234. doi:10.1016/S0031-9384(99)00053-0. ISSN 0031-9384. PMID 10477054. S2CID 37225025.
- ^ Erdmann EO (1855). Dissertatio de saccharo lactico et amylaceo [Dissertation on milk sugar and starch] (Thesis) (in Latin). University of Berlin.
- ^ "Jahresbericht über die Fortschritte der reinen, pharmaceutischen und technischen Chemie" [Annual report on progress in pure, pharmaceutical, and technical chemistry] (in German). 1855. pp. 671–673. see especially p. 673.
- ^ Pasteur L (1856). "Note sur le sucre de lait" [Note on milk sugar]. Comptes rendus (in French). 42: 347–351.
From page 348: Je propose de le nommer lactose. (I propose to name it lactose.)
- ^ Berthelot M (1860). "Chimie organique fondée sur la synthèse" [Organic chemistry based on synthesis]. Mallet-Bachelier (in French). 2. Paris, France: 248–249.
- ^ "Galactose" — from the Ancient Greek γάλακτος (gálaktos, “milk”).
- ^ Fischer E, Morrell RS (1894). "Ueber die Configuration der Rhamnose und Galactose" [On the configuration of rhamnose and galactose]. Berichte der Deutschen Chemischen Gesellschaft zu Berlin (in German). 27: 382–394. doi:10.1002/cber.18940270177. The configuration of galactose appears on page 385.
External links
[edit]- Media related to Galactose at Wikimedia Commons